Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | PAK4 | O96013 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | LTK | P29376 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | CDK7 | P50613 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | MST1R | Q04912 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12833213 | 0.84 | EGLN1 (0.38) | JAK3DYRK1AJAK2TTBK1TTBK2 | |
| SCHEMBL9918650 | 0.69 | AXL (0.41) | JAK3JAK2NOTUM | |
| SCHEMBL12832928 | 0.69 | LRRK2 (0.45) | JAK3LRRK2JAK2NUDT1IKBKB | |
| SCHEMBL9918651 | 0.68 | PRKCI (0.40) | JAK3JAK2NUDT1SYKCDK8 | |
| SCHEMBL9921698 | 0.67 | TTBK1 (0.31) | TTBK1TTBK2 | |
| SCHEMBL9918659 | 0.67 | TTBK1 (0.31) | TTBK1TTBK2 | |
| SCHEMBL24628649 | 0.66 | JAK2 (0.42) | JAK3PRKD3MAP4K4PAK4PDGFRB | |
| SCHEMBL9918654 | 0.65 | NUDT1 (0.52) | JAK3NUDT1 | |
| SCHEMBL3254384 | 0.63 | NUDT1 (0.63) | JAK3PRKD3MAP4K4PAK4PDGFRB | |
| SCHEMBL15059574 | 0.63 | PDE3B (0.61) | JAK3PRKD3MAP4K4PAK4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK3 3/4885PRKD3 473/4885MAP4K4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.